Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun;14(6):767-773.
doi: 10.1111/jdi.14005. Epub 2023 Mar 15.

Association of glucagon-like peptide-1 receptor agonist treatment with gastric residue in an esophagogastroduodenoscopy

Toshiko Kobori  1 , Yukiko Onishi  1 , Yoko Yoshida  1 , Tazu Tahara  1 , Takako Kikuchi  1 , Tetsuya Kubota  1 , Masahiko Iwamoto  1 , Tomonobu Sawada  1 , Reo Kobayashi  1 , Hiroaki Fujiwara  2 , Masato Kasuga  1
Affiliations

Association of glucagon-like peptide-1 receptor agonist treatment with gastric residue in an esophagogastroduodenoscopy

Toshiko Kobori et al. J Diabetes Investig. 2023 Jun.

Abstract

Aims/introduction: Previous studies have reported that the glucagon-like peptide-1 receptor agonist (GLP-1RA) delays gastric emptying, and gastric emptying was assessed by the 13 C breath test or paracetamol absorption technique. However, neither of them is clinically familiar in real-world clinical practice. The purpose of the present study was to investigate the association between GLP-1RA treatment and gastric residue in an esophagogastroduodenoscopy.

Materials and methods: This study was a matched pair case-control study. The study population consisted of 1,128 individuals with diabetes who had esophagogastroduodenoscopy at our clinic between July 2020 and June 2022. To account for differences in characteristics, such as age, sex, insulin treatment and glycated hemoglobin, we carried out a one-to-one nearest neighbor propensity score matching analysis between diabetes patients with and without GLP-1RA treatment. After matching, we compared the presence of gastric residue in an esophagogastroduodenoscopy by the McNemar test between patients with and without GLP-1RA treatment.

Results: After the propensity score matching, we selected 205 pairs. In the propensity score-matched comparison, the proportion of gastric residue was statistically significantly higher in the GLP-1RA treatment group (0.49% vs 5.4%, P = 0.004). The details of GLP-1RA prescribed for the 11 patients with gastric residue were liraglutide once daily 1.8 mg (n = 2), dulaglutide once weekly 0.75 mg (n = 5), semaglutide once weekly 0.5 mg (n = 2) and semaglutide once weekly 1.0 mg (n = 2).

Conclusion: GLP-1RA treatment is associated with gastric residue in an esophagogastroduodenoscopy in patients with diabetes.

Keywords: Esophagogastroduodenoscopy; Gastric residue; Glucagon-like peptide-1 receptor agonist treatment.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Patient selection flow for propensity score matching. GLP‐1RA, glucagon‐like peptide‐1 receptor agonist; HbA1c, glycated hemoglobin.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Draznin B, Aroda VR, Bakris G, et al. 9. Pharmacologic approaches to glycemic treatment: Standards of medical Care in Diabetes‐2022. Diabetes Care 2022; 45: S125–s143. - PubMed
    1. Bouchi R, Kondo T, Ohta Y, et al. A proposed algorithm for pharmacotherapy in people with type 2 diabetes. J Japan Diabetes Soc 2022; 65: 419–434 (Japanese).
    1. Kuwata H, Yabe D, Murotani K, et al. Effects of glucagon‐like peptide‐1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study. J Diabetes Investig 2021; 12: 2162–2171. - PMC - PubMed
    1. Quast DR, Nauck MA, Schenker N, et al. Macronutrient intake, appetite, food preferences and exocrine pancreas function after treatment with short‐ and long‐acting glucagon‐like peptide‐1 receptor agonists in type 2 diabetes. Diabetes Obes Metab 2021; 23: 2344–2353. - PubMed
    1. Quast DR, Schenker N, Menge BA, et al. Effects of Lixisenatide versus Liraglutide (short‐ and long‐acting GLP‐1 receptor agonists) on esophageal and gastric function in patients with type 2 diabetes. Diabetes Care 2020; 43: 2137–2145. - PubMed

MeSH terms